1. Single- and Multi-Fraction Stereotactic Radiosurgery Dose Tolerances of the Optic Pathways
- Author
-
Milano, Michael T, Grimm, Jimm, Soltys, Scott G, Yorke, Ellen, Moiseenko, Vitali, Tomé, Wolfgang A, Sahgal, Arjun, Xue, Jinyu, Ma, Lijun, Solberg, Timothy D, Kirkpatrick, John P, Constine, Louis S, Flickinger, John C, Marks, Lawrence B, and El Naqa, Issam
- Subjects
Cancer ,Rare Diseases ,Brain Cancer ,Neurosciences ,Eye Disease and Disorders of Vision ,Brain Disorders ,Patient Safety ,6.5 Radiotherapy and other non-invasive therapies ,Evaluation of treatments and therapeutic interventions ,Eye ,Adenoma ,Blindness ,Cavernous Sinus ,Craniopharyngioma ,Humans ,Maximum Tolerated Dose ,Meningeal Neoplasms ,Meningioma ,Models ,Biological ,Models ,Theoretical ,Optic Chiasm ,Optic Nerve ,Organs at Risk ,Pituitary Neoplasms ,Radiation Dose Hypofractionation ,Radiation Tolerance ,Radiosurgery ,Radiotherapy Dosage ,Re-Irradiation ,Skull Base Neoplasms ,Visual Acuity ,Visual Fields ,Other Physical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
PurposeDosimetric and clinical predictors of radiation-induced optic nerve/chiasm neuropathy (RION) after single-fraction stereotactic radiosurgery (SRS) or hypofractionated (2-5 fractions) radiosurgery (fSRS) were analyzed from pooled data that were extracted from published reports (PubMed indexed from 1990 to June 2015). This study was undertaken as part of the American Association of Physicists in Medicine Working Group on Stereotactic Body Radiotherapy, investigating normal tissue complication probability (NTCP) after hypofractionated radiation.Methods and materialsEligible studies described dose delivered to optic nerve/chiasm and provided crude or actuarial toxicity risks, with visual endpoints (ie, loss of visual acuity, alterations in visual fields, and/or blindness/complete vision loss). Studies of patients with optic nerve sheath tumors, optic nerve gliomas, or ocular/uveal melanoma were excluded to obviate direct tumor effects on visual outcomes, as were studies not specifying causes of vision loss (ie, tumor progression vs RION).ResultsThirty-four studies (1578 patients) were analyzed. Histologies included pituitary adenoma, cavernous sinus meningioma, craniopharyngioma, and malignant skull base tumors. Prior resection (76% of patients) did not correlate with RION risk (P = .66). Prior irradiation (6% of patients) was associated with a crude 10-fold increased RION risk versus no prior radiation therapy. In patients with no prior radiation therapy receiving SRS/fSRS in 1-5 fractions, optic apparatus maximum point doses resulting in
- Published
- 2021